The FDA Type-C meeting in Q2 2026 is the primary binary catalyst — a positive outcome could unlock partnership interest and extend runway. The EASL data presentations (May 28-30) may provide near-term volatility. Monitor for any partnership or financing announcements alongside the FDA readout.
Price Chart
Executive Summary
Galectin Therapeutics reported Q1 2026 results with a net loss of $5.1M ($0.08/share), narrower than the $9.6M loss in Q1 2025. Cash burn continues, with cash dropping to $14.1M from $17.7M at year-end 2025. The company highlighted upcoming catalysts: EASL data presentations and an FDA Type-C meeting in Q2 2026. No revenue or guidance was reported, and the EPS miss vs consensus (-33%) is largely mechanical for this pre-revenue biotech. The stock's historical pattern shows negative drift after filings, and the clinical binary event (FDA meeting) is the primary driver, not quarterly financials.
Key Financial Metrics
Key Facts
- Net loss applicable to common stock of $5.1M ($0.08/share) for Q1 2026 vs $9.6M ($0.15/share) in Q1 2025
- Cash and cash equivalents of $14.1M as of March 31, 2026, down from $17.7M at December 31, 2025
- Company has $10M available under a line of credit from its chairman; cash runway through May 2027
- R&D expenses fell to $2.2M from $6.5M YoY due to timing of NAVIGATE trial expenditures
- Upcoming catalysts: oral and poster presentations at EASL Congress (May 27-30, 2026) and an in-person Type-C FDA meeting in Q2 2026
- No revenue reported; pre-revenue clinical-stage biotech
- EPS of -$0.08 missed consensus estimate of -$0.06 (-33.3% miss)
Financial Impact
Net loss improved 47% YoY to $5.1M; cash burn of ~$3.6M in Q1 2026 vs ~$9.6M operating loss in Q1 2025
Risk Factors
- Cash runway only through May 2027; additional financing likely needed before then
- FDA meeting outcome is binary — negative feedback could severely impair stock
- No approved therapies for MASH cirrhosis; regulatory path uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-021496 |
| Document: ef20073003_8k.htm | 0001140361-26-021496 |
| Document: 0001140361-26-021496-index-headers.html | 0001140361-26-021496 |
| Document: 0001140361-26-021496-index.html | 0001140361-26-021496 |
| Document: 0001140361-26-021496.txt | 0001140361-26-021496 |
| 8-K Data (Synthetic) | 0001140361-26-021496 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.38 (−8.40%) |
Oct 13, 2026 14d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.38 (+8.40%) |
Oct 6, 2026 21d ago | Press Release | $3.76 | awaiting T+20 | — | $3.38 (−10.11%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.38 (−1.74%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.38 (−1.74%) |
Aug 4, 2026 12w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.38 (+13.04%) |
Jun 30, 2026 16w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.38 (−21.94%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.38 (+55.76%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.38 (+55.76%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.38 (+43.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers